NIMG-72. CEREBRAL BLOW FLOW AND SUV TRENDS IN PET/MRI FOLLOWING BEVACIZUMAB ADMINISTRATION IN GLIOBLASTOMA

BACKGROUND: Bevacizumab (BEV) is an antibody directed at vascular endothelial growth factor (VEGF) and holds FDA approval in recurrent glioblastoma (GBM). Pseudoprogression with necrosis is a common clinical concern in GBM, and BEV is useful in treating both tumor and necrosis. Though conventionally...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neuro Oncol
Huvudupphovsmän: Corbin, Zachary A, Zaharchuk, Greg, Spielman, Daniel M, Recht, Lawrence D
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2017
Ämnen:
Abstracts
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693070/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.644
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk